Qualigen Therapeutics, Inc. (QLGN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 16, 2022 7:30 AM EDTQ2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021
Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Companys diversified product portfolio
CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,... More
